Developing The First Disease Modifying Drug to Regenerate Peripheral Nerves
FIRST GOAL HIT(You can still invest)
$73,002
raised from 33 investors
INVEST
min $1,000
INVESTMENT TERMS
$500M
valuation cap
Future Equity
$250,
$500,
$1K,
$10K
A Future Equity Agreement (SAFE) gives you the right to future shares in the company. If you invest, you're betting the company will be worth more than $500M eventually.
WinSanTor has a drug in FDA trials that shows significant promise in combating neuropathy. Neuropathy causes debilitating loss of feeling, particularly in digits that can impede simple function and even walking. It’s generally caused by diabetes, chemotherapy, or nervous system disease. This is a significant global market opportunity without similar competing compounds. The drug has been in use in western countries for 30 years which should be helpful to its approval process. In addition, WinSanTor has transitioned this compound from tablet form to topical. This reformulation may be an additional opportunity for the company for other ingestible tablets that may be converted to topical use.